Equities Analysts Offer Predictions for Reneo Pharmaceuticals, Inc.’s Q2 2022 Earnings (NASDAQ:RPHM)

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHMGet Rating) – Stock analysts at Jefferies Financial Group lifted their Q2 2022 EPS estimates for shares of Reneo Pharmaceuticals in a research note issued to investors on Tuesday, May 10th. Jefferies Financial Group analyst E. Yang now forecasts that the company will post earnings of ($0.61) per share for the quarter, up from their previous forecast of ($0.67). Jefferies Financial Group also issued estimates for Reneo Pharmaceuticals’ Q3 2022 earnings at ($0.70) EPS, Q4 2022 earnings at ($0.80) EPS, FY2022 earnings at ($2.64) EPS, FY2023 earnings at ($2.49) EPS, FY2024 earnings at ($2.65) EPS, FY2025 earnings at ($1.86) EPS and FY2026 earnings at $0.74 EPS.

RPHM has been the topic of a number of other research reports. SVB Leerink reaffirmed an “outperform” rating on shares of Reneo Pharmaceuticals in a research report on Tuesday. Robert W. Baird started coverage on shares of Reneo Pharmaceuticals in a research report on Wednesday, January 26th. They set an “outperform” rating and a $28.00 price target on the stock. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $29.00.

Shares of RPHM opened at $2.12 on Friday. The stock has a market capitalization of $51.86 million and a P/E ratio of -1.11. The firm’s fifty day simple moving average is $2.98 and its two-hundred day simple moving average is $5.67. Reneo Pharmaceuticals has a 12 month low of $2.03 and a 12 month high of $12.78.

Reneo Pharmaceuticals (NASDAQ:RPHMGet Rating) last posted its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.16.

Several hedge funds have recently added to or reduced their stakes in RPHM. Morgan Stanley bought a new position in shares of Reneo Pharmaceuticals during the 2nd quarter worth about $291,000. BlackRock Inc. boosted its position in shares of Reneo Pharmaceuticals by 1.5% during the 3rd quarter. BlackRock Inc. now owns 294,281 shares of the company’s stock worth $2,191,000 after purchasing an additional 4,457 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Reneo Pharmaceuticals by 67.4% during the 3rd quarter. Geode Capital Management LLC now owns 120,668 shares of the company’s stock worth $898,000 after purchasing an additional 48,599 shares in the last quarter. Rock Springs Capital Management LP boosted its position in shares of Reneo Pharmaceuticals by 1.3% during the 3rd quarter. Rock Springs Capital Management LP now owns 1,143,185 shares of the company’s stock worth $8,517,000 after purchasing an additional 14,161 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Reneo Pharmaceuticals in the 4th quarter worth about $115,000. 79.53% of the stock is currently owned by institutional investors.

About Reneo Pharmaceuticals (Get Rating)

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.

Further Reading

Earnings History and Estimates for Reneo Pharmaceuticals (NASDAQ:RPHM)

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.